{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:19:43Z","timestamp":1789579183300,"version":"build-2803163510"},"reference-count":78,"publisher":"Bioscientifica","issue":"4","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neoadjuvant therapy has an emerging role in the management of locally advanced thyroid cancer. Recent developments in systemic therapies, particularly with the introduction of multikinase inhibitors and selective inhibitors, have demonstrated promising results. The objective of this review is to delve into the implications of these developments and their potential impact on the management of advanced thyroid cancers, which initially present as borderline resectable or unresectable. For differentiated thyroid cancer and poorly differentiated thyroid cancer, agents such as lenvatinib have shown substantial tumor reduction, facilitating surgical resection. Similarly, for medullary thyroid cancer, selpercatinib have exhibited interesting response rates, enhancing the feasibility of surgery with reduced morbidity in limited clinical case series of patients with RET mutations. In BRAF mutant ATC, the combination of BRAF and MEK inhibitors has significantly improved treatment protocols, providing a pathway to surgical intervention and significantly improving survival rates. The addition of immune checkpoint inhibitors to these regimens showed further extension of survival and reduced recurrence rates in retrospective studies that still need confirmation. Despite these preliminary favorable results, neoadjuvant therapies are not without challenges. The risk of adverse events, particularly related to the inhibition of the VEGF pathway, necessitates careful patient selection and management. The variability in tumor responses and the potential for serious complications underscore the need for continued research to refine these approaches in this difficult patient population.<\/jats:p>","DOI":"10.1530\/erc-24-0185","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T05:59:32Z","timestamp":1739858372000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":4,"title":["Transforming thyroid cancer management: the impact of neoadjuvant therapy"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7450-5832","authenticated-orcid":true,"given":"In\u00e9s","family":"Califano","sequence":"first","affiliation":[{"name":"Endocrinology Service Instituto de Oncolog\u00eda \u201cAngel H Roffo\u201d University of Buenos Aires 1 , ,","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2542-3830","authenticated-orcid":true,"given":"Gregory","family":"Randolph","sequence":"additional","affiliation":[{"name":"Thyroid and Parathyroid Endocrine Surgical Division, Massachusetts Eye and Ear, Harvard Medical School 2 , ,","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-7085","authenticated-orcid":true,"given":"Fabi\u00e1n","family":"Pitoia","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Hospital de Cl\u00ednicas, University of Buenos Aires 3 , ,","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"2026070905405662900_bib1","doi-asserted-by":"crossref","first-page":"TPS6105","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS6105","article-title":"A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer","volume":"41","author":"Abdelhamid","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026070905405662900_bib2","first-page":"e1466","article-title":"Neoadjuvant lenvatinib for inoperable thyroid cancer: a case report and literature review","volume":"5","author":"Alshehri","year":"2022","journal-title":"Cancer Rep"},{"key":"2026070905405662900_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/thy.2011.0243","article-title":"Neoadjuvant chemotherapy in 29 patients with locally advanced follicular or H\u00fcrthle cell thyroid carcinoma: a phase 2 study","volume":"22","author":"Besic","year":"2012","journal-title":"Thyroid"},{"key":"2026070905405662900_bib4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1089\/thy.2012.0194","article-title":"Neoadjuvant chemotherapy in 16 patients with locally advanced papillary thyroid carcinoma","volume":"23","author":"Besic","year":"2013","journal-title":"Thyroid"},{"key":"2026070905405662900_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"key":"2026070905405662900_bib6","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1089\/thy.2012.0598","article-title":"Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer","volume":"24","author":"Blevins","year":"2014","journal-title":"Thyroid"},{"key":"2026070905405662900_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"2026070905405662900_bib9","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026070905405662900_bib10","first-page":"1184","article-title":"Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"key":"2026070905405662900_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ctrv.2018.06.019","article-title":"Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer","volume":"69","author":"Capdevila","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"2026070905405662900_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.572958","article-title":"Treatment of unresectable differentiated thyroid carcinoma with upfront external radiotherapy and salvage surgery: a STROBE-compliant retrospective cohort study","volume":"10","author":"Carrillo","year":"2021","journal-title":"Front Oncol"},{"key":"2026070905405662900_bib13","article-title":"Establishment and validation of a nomogram model for predicting distant metastasis in medullary thyroid carcinoma: an analysis of the SEER database based on the AJCC 8th TNM staging system","volume":"15","author":"Chen","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026070905405662900_bib14","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1177\/1078155218817109","article-title":"Wound healing complications with lenvatinib identified in a pharmacovigilance database","volume":"25","author":"Cheng","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2026070905405662900_bib15","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1200\/JCO.2009.27.4225","article-title":"Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib","volume":"28","author":"Cleary","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026070905405662900_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/thy.2022.0506","article-title":"Neoadjuvant selective RET inhibitor for medullary thyroid cancer: a case series","volume":"33","author":"Contrera","year":"2023","journal-title":"Thyroid"},{"key":"2026070905405662900_bib17","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/archotol.1997.01900050030003","article-title":"The surgical management of laryngotracheal invasion by well-differentiated papillary thyroid carcinoma","volume":"123","author":"Czaja","year":"1997","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2026070905405662900_bib18","first-page":"30","article-title":"BRAF mutation and the use of vemurafenib in advanced papillary thyroid cancer","volume":"27","author":"Dadu","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"2026070905405662900_bib19","article-title":"Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report","volume":"12","author":"Dam\u00e1sio","year":"2022","journal-title":"Eur Thyroid J"},{"key":"2026070905405662900_bib20","first-page":"370","article-title":"Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer","volume":"62","author":"Danilovic","year":"2018","journal-title":"Arch Endocrinol Metab"},{"key":"2026070905405662900_bib21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026070905405662900_bib22","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026070905405662900_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106625","article-title":"Neoadjuvant dabrafenib and trametinib for functional organ preservation in recurrent BRAF V600E-mutated papillary thyroid cancer","volume":"147","author":"Farlow","year":"2023","journal-title":"Oral Oncol"},{"key":"2026070905405662900_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/fon-2019-0099","article-title":"Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma","volume":"15","author":"Gay","year":"2019","journal-title":"Future Oncol"},{"key":"2026070905405662900_bib25","first-page":"e73","article-title":"Neoadjuvant Lenvatinib in advanced unresectable medullary thyroid carcinoma: a case report","volume":"6","author":"Golingan","year":"2019","journal-title":"AACE Clin Case Rep"},{"key":"2026070905405662900_bib26","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1007\/s12325-021-01940-2","article-title":"Outcome of patients with locally advanced metastatic medullary thyroid cancer and induction therapy with tyrosine kinase inhibitors in Slovenia","volume":"38","author":"Grasic Kuhar","year":"2021","journal-title":"Adv Ther"},{"issue":"Suppl 2","key":"2026070905405662900_bib75","first-page":"S","article-title":"Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review","volume":"13","author":"Guerra","year":"2013","journal-title":"BMC Surg"},{"key":"2026070905405662900_bib73","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070905405662900_bib74","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.0.CO;2-1","article-title":"Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival","volume":"91","author":"Haigh","year":"2001","journal-title":"Cancer"},{"key":"2026070905405662900_bib27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1089\/thy.2023.0573","article-title":"Checkpoint inhibition in addition to dabrafenib\/trametinib for BRAFV600E-mutated anaplastic thyroid carcinoma","volume":"34","author":"Hamidi","year":"2024","journal-title":"Thyroid"},{"key":"2026070905405662900_bib28","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hed.23406","article-title":"Resection margins and prognosis in locally invasive thyroid cancer","volume":"36","author":"Hartl","year":"2014","journal-title":"Head Neck"},{"key":"2026070905405662900_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"2026070905405662900_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/ve.2023.0038","article-title":"Recurrent laryngeal nerve recovery after neoadjuvant therapy for BRAF-mutated anaplastic thyroid cancer","volume":"11","author":"Hawes","year":"2024","journal-title":"VideoEndocrinology"},{"key":"2026070905405662900_bib31","article-title":"A case of unresectable papillary thyroid carcinoma treated with lenvatinib as neoadjuvant chemotherapy","volume":"11","author":"Iwasaki","year":"2020","journal-title":"Case Rep Endocrinol"},{"key":"2026070905405662900_bib32","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1002\/hed.26527","article-title":"Neoadjuvant selpercatinib for advanced medullary thyroid cancer","volume":"43","author":"Jozaghi","year":"2021","journal-title":"Head Neck"},{"key":"2026070905405662900_bib33","doi-asserted-by":"crossref","first-page":"IJE33","DOI":"10.2217\/ije-2020-0014","article-title":"Neoadjuvant use of lenvatinib in locally advanced papillary thyroid carcinoma involving critical vessels","volume":"7","author":"Katoh","year":"2021","journal-title":"Int J Endocr Oncologia"},{"key":"2026070905405662900_bib34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/thy.2020.0206","article-title":"Real-world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer","volume":"31","author":"Koehler","year":"2021","journal-title":"Thyroid"},{"key":"2026070905405662900_bib35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s12020-020-02245-0","article-title":"Locally unresectable differentiated thyroid cancer: outcomes and perspectives","volume":"69","author":"Lamartina","year":"2020","journal-title":"Endocrine"},{"key":"2026070905405662900_bib36","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1245\/s10434-019-07314-x","article-title":"The prognosis of papillary thyroid cancer with initial distant metastasis is strongly associated with extensive extrathyroidal extension: a retrospective cohort study","volume":"27","author":"Lee","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"2026070905405662900_bib37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hed.27584","article-title":"Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer","volume":"46","author":"Maniakas","year":"2024","journal-title":"Head Neck"},{"key":"2026070905405662900_bib38","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3389\/fendo.2019.00712","article-title":"Neoadjuvant multikinase inhibitor in patients with locally advanced unresectable thyroid carcinoma","volume":"10","author":"Nava","year":"2019","journal-title":"Front Endocrinol"},{"key":"2026070905405662900_bib39","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1089\/thy.2016.0064","article-title":"Management of invasive differentiated thyroid cancer","volume":"26","author":"Nixon","year":"2016","journal-title":"Thyroid"},{"key":"2026070905405662900_bib40","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/his.15013","article-title":"Histological findings of thyroid cancer after lenvatinib therapy","volume":"83","author":"Okubo","year":"2023","journal-title":"Histopathology"},{"key":"2026070905405662900_bib70","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3390\/cancers12082323","article-title":"Clinical course from diagnosis to death in patients with well-differentiated thyroid cancer","volume":"12","author":"Park","year":"2020","journal-title":"Cancers"},{"key":"2026070905405662900_bib41","first-page":"8227","article-title":"Does timing of targeted therapy for metastatic renal cell carcinoma impact treatment toxicity and surgical complications? A comparison of primary and adjuvant approaches","volume":"23","author":"Patel","year":"2016","journal-title":"Can J Urol"},{"key":"2026070905405662900_bib42","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1089\/thy.2024.0090","article-title":"Neoadjuvant treatment of locally advanced thyroid cancer: a preliminary Latin American experience","volume":"34","author":"Pitoia","year":"2024","journal-title":"Thyroid"},{"key":"2026070905405662900_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11154-023-09818-0","article-title":"Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective","volume":"25","author":"Pitoia","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"key":"2026070905405662900_bib44","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/thy.2016.0395","article-title":"Patterns of treatment failure in anaplastic thyroid carcinoma","volume":"27","author":"Rao","year":"2017","journal-title":"Thyroid"},{"key":"2026070905405662900_bib46","doi-asserted-by":"crossref","first-page":"574","DOI":"10.21037\/gs.2017.08.05","article-title":"Complications from tracheal resection for thyroid carcinoma","volume":"6","author":"Rotolo","year":"2017","journal-title":"Gland Surg"},{"key":"2026070905405662900_bib47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.radonc.2019.03.033","article-title":"The role of external beam radiotherapy in the management of medullary carcinoma of the thyroid: a systematic review","volume":"136","author":"Rowell","year":"2019","journal-title":"Radiother Oncol"},{"key":"2026070905405662900_bib48","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/hed.27735","article-title":"Neoadjuvant therapy to improve resectability of advanced thyroid cancer: a real-world experience","volume":"46","author":"Russell","year":"2024","journal-title":"Head Neck"},{"key":"2026070905405662900_bib49","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1002\/lary.31304","article-title":"Recovery of recurrent laryngeal nerve function with neoadjuvant treatment: neural characterization","volume":"134","author":"Russell","year":"2024","journal-title":"Laryngoscope"},{"key":"2026070905405662900_bib51","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(13)70215-8","article-title":"Definition and management of radioactive iodine-refractory differentiated thyroid cancer","volume":"2","author":"Schlumberger","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070905405662900_bib52","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070905405662900_bib80","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1245\/s10434-024-15356-z","article-title":"Single institution experience in the management of locally advanced (pT4) differentiated thyroid carcinomas","volume":"31","author":"Sessa","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2026070905405662900_bib53","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/0046-8177(93)90136-5","article-title":"Pathologic staging of papillary carcinoma of the thyroid with airway invasion based on the anatomic manner of extension to the trachea: a clinicopathologic study based on 22 patients who underwent thyroidectomy and airway resection","volume":"24","author":"Shin","year":"1993","journal-title":"Hum Pathol"},{"key":"2026070905405662900_bib54","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hed.23619","article-title":"Management of invasive well-differentiated thyroid cancer: an American Head and Neck Society consensus statement. AHNS consensus statement","volume":"36","author":"Shindo","year":"2014","journal-title":"Head Neck"},{"key":"2026070905405662900_bib55","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1089\/thy.1998.8.1113","article-title":"Effectiveness of preoperative radioactive iodine (131I) therapy for locally advanced papillary thyroid cancer: a case report","volume":"8","author":"Shingu","year":"1998","journal-title":"Thyroid"},{"key":"2026070905405662900_bib69","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/hed.27025","article-title":"American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment","volume":"44","author":"Shonka","year":"2022","journal-title":"Head Neck"},{"key":"2026070905405662900_bib56","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1089\/thy.2023.0136","article-title":"Return of vocal fold motion and surgical preservation of invaded recurrent laryngeal nerves after the use of neoadjuvant therapy in patients presenting with advanced thyroid cancer and vocal fold paralysis: the lazarus effect","volume":"33","author":"Silver Karcioglu","year":"2023","journal-title":"Thyroid"},{"key":"2026070905405662900_bib57","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clon.2010.03.013","article-title":"Anaplastic thyroid carcinoma: pathogenesis and emerging therapies","volume":"22","author":"Smallridge","year":"2010","journal-title":"Clin Oncol"},{"key":"2026070905405662900_bib58","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1089\/thy.2020.0251","article-title":"Re: \u201cComplete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in V600E-Mutated Anaplastic Thyroid Carcinoma\u201d by Wang et al","volume":"30","author":"Smulever","year":"2020","journal-title":"Thyroid"},{"key":"2026070905405662900_bib59","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.21873\/anticanres.13537","article-title":"Clinical characteristics associated with lenvatinib-induced fistula and tumor-related bleeding in patients with thyroid cancer","volume":"39","author":"Staub","year":"2019","journal-title":"Anticancer Res"},{"key":"2026070905405662900_bib60","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000494880","article-title":"Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report","volume":"8","author":"Stewart","year":"2019","journal-title":"Eur Thyroid J"},{"key":"2026070905405662900_bib72","doi-asserted-by":"crossref","DOI":"10.20945\/2359-3997000000659","article-title":"Neoadjuvant therapy with anlotinib in a locally advanced and pulmonary metastasis PTC patient harboring TERT promoter and BRAFV600E mutations: a case report","volume":"67","author":"Su","year":"2023","journal-title":"Arch Endocrinol Metab"},{"key":"2026070905405662900_bib61","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort open-label registrational phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070905405662900_bib81","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026070905405662900_bib62","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"2026070905405662900_bib63","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijscr.2017.10.010","article-title":"Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: a case report","volume":"41","author":"Tsuboi","year":"2017","journal-title":"Int J Surg Case Rep"},{"key":"2026070905405662900_bib79","volume-title":"AJCC Cancer Staging Manual","author":"Tuttle","year":"2017","edition":"8th edition"},{"key":"2026070905405662900_bib77","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000514182","article-title":"Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer","volume":"10","author":"Valerio","year":"2021","journal-title":"Eur Thyroid J"},{"key":"2026070905405662900_bib64","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026070905405662900_bib76","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1089\/thy.2019.0133","article-title":"Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma","volume":"29","author":"Wang","year":"2019","journal-title":"Thyroid"},{"key":"2026070905405662900_bib68","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026070905405662900_bib65","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070905405662900_bib66","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/his.14550","article-title":"Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases","volume":"80","author":"Xu","year":"2022","journal-title":"Histopathology"},{"key":"2026070905405662900_bib78","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1017\/S0022215123000506","article-title":"Neoadjuvant tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a single centre case series","volume":"137","author":"Yeo","year":"2023","journal-title":"J Laryngol Otol"},{"key":"2026070905405662900_bib71","article-title":"Preoperative neoadjuvant targeted therapy with apatinib for inoperable differentiated thyroid cancer: a case report","volume":"100","author":"Zhang","year":"2021","journal-title":"Medicine"},{"key":"2026070905405662900_bib67","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1089\/thy.2022.0504","article-title":"Surgery after BRAF-directed therapy is associated with improved survival in BRAFV600E mutant anaplastic thyroid cancer: a single-center retrospective cohort study","volume":"33","author":"Zhao","year":"2023","journal-title":"Thyroid"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/4\/ERC-24-0185.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/4\/ERC-24-0185.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0185\/144684\/erc-24-0185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0185\/144684\/erc-24-0185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:41:10Z","timestamp":1783590070000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/4\/e240185\/25870\/Transforming-thyroid-cancer-management-the-impact"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-24-0185","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"article-number":"e240185"}}